| DAYTRANA™
Transdermal Patch Approved by FDA for Treatment of
ADHD
DAYTRANA (methylphenidate
transdermal system), is the first and only non-oral medication
for the treatment of attention deficit hyperactivity disorder
(ADHD). DAYTRANA, a once daily transdermal patch formulation
of methylphenidate, will be available in 10 mg, 15 mg,
20 mg and 30 mg dosage strengths. “The FDA’s approval
of DAYTRANA offers an important new option in the treatment
of ADHD in children,” said Robert Findling, MD, lead investigator
and Professor of Psychiatry; Director, Division of Adolescent
and Child Psychiatry, Case Western University. “DAYTRANA
has been shown to be effective and generally well tolerated
in clinical studies, and offers ADHD treatment in the
convenient form of a patch.”
|
